Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03139253

Enrollment

120

Registered

2017-05-03

Start date

2017-05-30

Completion date

2017-06-30

Last updated

2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antimicrobial Susceptibility Testing, Triple Therapy

Keywords

Helicobacter Pylori Infection, Antimicrobial susceptibility testing (AST), Triple Therapy

Brief summary

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

Interventions

DRUGamoxicillin

amoxicillin 1000 mg bid. for 14 days

DRUGclarithromycin

clarithromycin 500 mg bid. for 14 days.

DRUGtinidazole

tinidazole 500 mg bid. for 14 days.

DRUGlevofloxacin

levofloxacin 500 mg qd. for 14 days.

DRUGfurazolidone

furazolidone 100 mg bid. for 14 days.

DRUGtetracycline

tetracycline 750 mg bid. for 14 days.

DRUGIlaprazole

Ilaprazole 5 mg bid. for 14 days.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Consecutive patients who are 18-70 years old with persistent H. pylori infection after first or second line treatment attempts.

Exclusion criteria

* Enable to undergo upper endoscopy; * Patients with gastrectomy, acute GI bleeding and advanced gastric cancer; * Known or suspected allergy to study medications; * Taking bismuth and antibiotics in the previous four weeks, or taking proton pump inhibitor and H2-receptor blockers in the previous two weeks; * Currently pregnant or lactating * Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Design outcomes

Primary

Measure	Time frame
Eradication rate of AST guided triple therapy	3 months

Secondary

Measure	Time frame
the rate of improving dyspepsia symptoms after H. pylori eradication	3 months
the rate of adverse events happening	3 months
the rate of good compliance (take pills more than 90%)	3 months

Contacts

Primary ContactLi Yanqing, MD, PhD

liyanqing@sdu.edu.cn86-531-82169236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026